Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of Oral Verdiperstat (BHV-3241) in Patients With Semantic Variant Primary Progressive Aphasia (svPPA) Due to TDP-43 Pathology

Inclusion Criteria: 1. Between 18 and 85 years of age (inclusive) at the initial screening visit; 2. Meets 2011 consensus criteria for svPPA (Gorno-Tempini et al. 2011); 3. MRI at screening is consistent with the underlying svPPA with no large strokes or severe white matter disease (Fazekas Grade ≤2; Fazekas et al. 1987); 4. CDR® plus NACC FTLD (Miyagawa et al. 2020) global score at screening ≤1; 5. The following medications are allowed, but must be stable for 2 months prior to the initial screening visit: 1. Food and Drug Administration (FDA)-approved Alzheimer's disease (AD) medications…